Immune Therapy’s Cancer Promise Creates Research Rush

In In The News by Barbara Jacoby

By: Naomi Kresge and Robert Langreth From: bloomberg.com A new class of medicines that help the body’s own immune cells fight tumors could target a wide set of cancers, opening a $35 billion market for Merck (MRK) & Co., Bristol-Myers Squibb Co., AstraZeneca Plc and Roche (ROG) Holding AG. The drugmakers will use the world’s largest meeting of cancer doctors, …

CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer

In In The News by Barbara Jacoby

(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …